Benzinga | Apr 1, 2021 08:05AM EDT

Onconova Therapeutics Partner HanX Has Enrolled Three Patients In Second Dosing Cohort Of Phase 1 Study Of ON 123300

Onconova Therapeutics, Inc. (NASDAQ:ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, announces that its corporate partner HanX Biopharmaceuticals has enrolled three patients in the second dosing cohort of its Phase 1 study with ON 123300 in HR+ HER2- metastatic breast cancer and other advanced relapsed/refractory cancers in China.